



Provincial Health Services Authority

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca/terms-of-use and according to acceptable standards of care.

PROTOCOL CODE: BRLAACDT

DOCTOR'S ORDERS			Ht _____ cm	Wt _____ kg	BSA _____ m ²
REMINDER: Please ensure drug allergies and previous bleomycin are documented on the Allergy & Alert Form					
DATE:	To be given:	Cycle #:			
Date of Previous Cycle: _____					
<input type="checkbox"/> Delay Treatment _____ week(s)					
<input type="checkbox"/> CBC & Diff, platelets day of treatment					
May proceed with doses as written if within 96 hours ANC greater than or equal to 1.5 x 10⁹/L, Platelets greater than or equal to 90 x 10⁹/L					
Dose modification for: <input type="checkbox"/> Hematology <input type="checkbox"/> Other Toxicity _____					
Proceed with treatment based on blood work from _____					
PREMEDICATIONS: Patient to take own supply. RN/Pharmacist to confirm _____.					
dexamethasone <input type="checkbox"/> 8 mg or <input type="checkbox"/> 12 mg (select one) PO 30 to 60 minutes prior to AC treatment					
and select ONE of the following:					
<input type="checkbox"/>	ondansetron 8 mg PO 30 to 60 minutes prior to AC treatment				
<input type="checkbox"/>	aprepitant 125 mg PO 30 to 60 minutes prior to AC treatment				
<input type="checkbox"/>	ondansetron 8 mg PO 30 to 60 minutes prior to AC treatment				
<input type="checkbox"/>	netupitant-palonosetron 300 mg-0.5 mg PO 30 to 60 minutes prior to AC treatment				
For DOCEtaxel Cycles: dexamethasone 8 mg PO bid for 3 days starting one day prior to DOCEtaxel; patient must receive 3 doses prior to treatment					
Optional: Frozen gloves starting 15 minutes before DOCEtaxel infusion until 15 minutes after end of DOCEtaxel infusion; gloves should be changed after 45 minutes of wearing.					
<input type="checkbox"/> Other: _____					
Have Hypersensitivity Reaction Tray and Protocol Available					
CHEMOTHERAPY: (Note – continued over 2 pages)					
<input type="checkbox"/> CYCLE # _____ (Cycle 1-4)					
DOXOrubicin 60 mg/m² x BSA = _____ mg					
<input type="checkbox"/> Dose Modification: _____ % = _____ mg/m ² x BSA = _____ mg					
IV push					
cyclophosphamide 600 mg/m² x BSA = _____ mg					
<input type="checkbox"/> Dose Modification: _____ % = _____ mg/m ² x BSA = _____ mg					
IV in 100 to 250 mL NS over 20 minutes to 1 hour					
*** SEE PAGE 2 FOR CHEMOTHERAPY CYCLES 5 TO 8 ***					
DOCTOR'S SIGNATURE:					UC SIGNATURE:



Provincial Health Services Authority

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca/terms-of-use and according to acceptable standards of care.

PROTOCOL CODE: BRLAACDT

Page 2 of 3

DOCTOR'S ORDERS

DATE:

To be given:

Cycle #:

CHEMOTHERAPY: (Continued)

***** SEE PAGE 1 FOR CHEMOTHERAPY CYCLES 1 TO 4 *****

CYCLE # 5 (Cycle 1 of trastuzumab/DOCEtaxel)

trastuzumab 8 mg/kg x _____ kg = _____ mg IV in NS 250 mL over 1 hour 30 minutes; observe for 1 hour post infusion

Pharmacy to select trastuzumab brand as per Provincial Systemic Therapy Policy III-190

Drug	Brand (Pharmacist to complete. Please print.)	Pharmacist Initial and Date
trastuzumab		

DOCEtaxel 100 mg/m² x BSA = _____ mg

Dose Modification: _____ % = _____ mg/m² x BSA = _____ mg

IV in NS 250 to 500 mL (non-DEHP bag) over 1 hour (Use non-DEHP tubing)

CYCLE # 6

trastuzumab 6 mg/kg x _____ kg = _____ mg IV in NS 250 mL over 1 hour; observe for 30 minutes post infusion

Pharmacy to select trastuzumab brand as per Provincial Systemic Therapy Policy III-190

Drug	Brand (Pharmacist to complete. Please print.)	Pharmacist Initial and Date
trastuzumab		

DOCEtaxel 100 mg/m² x BSA = _____ mg

Dose Modification: _____ % = _____ mg/m² x BSA = _____ mg

IV in NS 250 to 500 mL (non-DEHP bag) over 1 hour (Use non-DEHP tubing)

CYCLE # 7 and # 8:

trastuzumab 6 mg/kg x _____ kg = _____ mg IV in NS 250 mL over 30 minutes; observe for 30 minutes post infusion (not required after 3 treatments with no reaction)

Pharmacy to select trastuzumab brand as per Provincial Systemic Therapy Policy III-190

Drug	Brand (Pharmacist to complete. Please print.)	Pharmacist Initial and Date
trastuzumab		

DOCEtaxel 100 mg/m² x BSA = _____ mg

Dose Modification: _____ % = _____ mg/m² x BSA = _____ mg

IV in NS 250 to 500 mL (non-DEHP bag) over 1 hour (Use non-DEHP tubing)

acetaminophen 325 to 650 mg PO PRN for headache and rigors

DOCTOR'S SIGNATURE:

UC SIGNATURE:



Provincial Health Services Authority

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca/terms-of-use and according to acceptable standards of care.

PROTOCOL CODE: BRLAACDT

Page 3 of 3

DOCTOR'S ORDERS	
DATE:	
RETURN APPOINTMENT ORDERS	
<input type="checkbox"/> Return in three weeks for Doctor and Cycle _____ <input type="checkbox"/> Last Cycle. Return in three weeks for BRAJTR (to continue single agent trastuzumab)	
CBC & Diff, Platelets prior to each cycle Prior to Cycle 5: Bilirubin, ALT, Alk Phos If clinically indicated: <input type="checkbox"/> Tot. Prot <input type="checkbox"/> Albumin <input type="checkbox"/> Bilirubin <input type="checkbox"/> GGT <input type="checkbox"/> Alk Phos. <input type="checkbox"/> LDH <input type="checkbox"/> ALT <input type="checkbox"/> Creatinine <input type="checkbox"/> Other tests: <input type="checkbox"/> MUGA scan or Echo (select one): prior to Cycle 5 and then every <input type="checkbox"/> 3 months or <input type="checkbox"/> 4 months until completion of treatment <input type="checkbox"/> Consults: <input type="checkbox"/> See general orders sheet for additional requests.	
DOCTOR'S SIGNATURE:	UC SIGNATURE: